Athira Pharma, Inc., (ATHA)

Trade ATHA now with
4/4/2022 8:00:21 AM Athira Pharma Doses First Subject In Phase 1 Clinical Trial Of ATH-1020 For Neuropsychiatric Conditions
3/21/2022 7:28:52 AM Athira Pharma Names Michael Panzara To Board
6/14/2021 7:36:28 AM Athira Pharma Names Rachel Lenington As Chief Technology Officer, Head Of Product Development Strategy
3/8/2021 7:11:40 AM Athira Pharma Appoints Barbara Kosacz To Board
1/20/2021 7:56:50 PM Athira Pharma Prices Public Offering Of 4 Mln Shares At $22.50/shr